WellPoint is on a mission to manage spiraling drug costs. Perhaps best known for its role in pushing Claritin over-the-counter, its OTC strategy provides real cost savings and also reveals the company's aggressive mindset for dealing with its critical cost drivers. Fresh from its Claritin OTC victory, WellPoint launched its latest expense-reduction program, GenericSelect, to promote generic substitution for all prescription drugs within certain therapeutic categories. And in a separate effort, WellPoint is exploring therapeutic substitution, the switch of one branded drug for another, when there is not a generic option in a class of drugs. If WellPoint demonstrates continued success with its strategies, managed care in general may begin to undertake the type of aggressive formulary management that was promised back in the early 1990s.
By Heather Slowik
2003 marks an anniversary of sorts for the pharmaceutical industry: call it Managed Care Mania. A decade ago, bracing for...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
